Hence, hybrid compounds combining HDAC‐inhibiting moieties with other cancer targets have been developed to overcome drug resistance and to synergistically enhance the anticancer activity of these novel compounds (Schobert and Biersack, 2017). This evidence concerns the gene HDAC9 and cancer.